Symeres has announced its acquisition of DGr Pharma, a consultancy specializing in drug development, aimed at enhancing its early-stage drug development services and accelerating IND-enabling capabilities for biopharma clients. This strategic move is backed by Keensight Capital, a prominent private equity firm focused on pan-European growth buyouts.
Founded in 2018 and headquartered in the Netherlands, DGr Pharma offers expertise in pre-clinical and clinical regulatory strategy, focusing on chemical-pharmaceutical development, quality assurance, and regulatory submissions. Their robust experience with both small and large molecules, including antibodies and oligonucleotides, will significantly bolster Symeres’ regulatory capabilities, allowing for a more comprehensive suite of services in drug discovery and development.
The integration of DGr Pharma’s Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) compliant pharmacokinetic data analysis services aligns seamlessly with Symeres’ offerings, enhancing data quality and regulatory readiness. This acquisition not only strengthens Symeres’ market position but also provides clients with a more efficient pathway to IND submission, reinforcing the company’s commitment to high-quality science and client support.
Guillaume Jetten, CEO of Symeres, emphasized that this acquisition enhances their ability to deliver integrated solutions across the drug development spectrum, while Kees Groen, CEO of DGr Pharma, expressed enthusiasm about the growth opportunities this partnership presents. Amit Karna from Keensight Capital noted that this acquisition will extend Symeres’ capabilities into complementary services and attractive drug classes, indicating a promising future for the newly expanded organization.
